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 1. INTRODUCTION 
      The enhancement of oral bioavailability of poor water soluble drugs remains one 
of the most challenging aspects of drug development. The development of solid 
dispersions as a practically viable method to enhance bioavailability of poorly 
water-soluble drugs overcame the limitations of previous approaches such as salt 
formation, solubalization by cosolvents, and particle size reduction.¹ 
The poor solubility and low dissolution rate of poorly water soluble drugs in 
the aqueous gastro-intestinal fluids often cause insufficient bioavailability.² 
Lipophilic molecules, especially those belonging to the bio pharmaceutics 
classification system (BCS) class II and IV, dissolve slowly, poorly and irregularly, 
and hence pose serious delivery challenges, like in complete release from the dosage 
form, poor bioavailability, increased food effect, and high inter-patient variability.³   
                 In 1961, Sekiguchi and Obi developed a practical method whereby many of 
the limitations with the bioavailability enhancement of poorly water soluble drugs 
can be overcome. This method, which was later, termed solid dispersion which 
involved the formation of eutectic mixture of drugs with water-soluble carriers by 
the melting of their physical mixtures.4   
           The term solid dispersion refers to a group of solid products consisting of at 
least two different compounds, generally a hydrophilic matrix and a hydrophobic 
drug. The matrix can be either crystalline or amorphous. The drug can be dispersed 
molecularly, in amorphous particle (clusters) or in crystalline particles.5 
            Solid dispersion can be prepared by various methods such as solvent 
evaporation and melting method. Solid dispersion technique has been extensively 
used to increase the solubility of a poorly water-soluble drug. According to this 
method, a drug is thoroughly dispersed in a water-soluble carrier by suitable 
method of preparation. The mechanism by which the solubility and the dissolution 
rate of the drug are increased includes: reduction  
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 of the particle size of drug to submicron size or to molecular size in the case where 
solid solution is obtained. The particle size reduction generally increases the rate of 
dissolution; secondly, the drug is changed from amorphous to crystalline form, the 
high energetic state which is highly soluble; finally, the wet ability of the drug 
particle is improved by the hydrophilic carrier.6 
Solid dispersion of drug helps to reduce the particle size of drug due to 
molecular dispersion.7 Particle size reduction by micronization or nanonization can 
enhance the dissolution rate; however, the apparent solubility remains unaltered. At 
the molecular level, polymorphs offer a limited solubility advantage because of a 
small difference in free energy. In contrast, amorphous systems with excess 
thermodynamic properties and lower energetic barrier can offer significant 
solubility benefits.8  
There were several ways in which bioavailability of the drug can be 
enhanced all of which aimed at increasing the surface area of the drugs which 
includes. Micronization, use of salt form, use of metastable polymorphs, solvent 
deposition, selective adsorption on insoluble carriers, solid dispersion, solute 
solvent complexation, complexation with cyclodextrins.9 
Hyperlipidemia or hyperlipoprotienemia or dyslipidemia is the presence of 
elevated or abnormal levels of lipids or lipoproteins in the blood. Lipid and 
lipoprotein abnormalities are extremely common in general population and are 
regarded as a highly modifiable risk factor for cardiovascular diseases due to 
influence of cholesterol. An individual’s specific biochemical and metabolic profile 
can often work against even the healthiest lifestyle. For these “biochemically 
challenged” patients, lipid-lowering agents such as the statins have literally 
provided a new lease on life. Atorvastatin is a selective competitive inhibitor of HMG 
CoA reductase. Atorvastatin reduces total cholesterol, LDL-cholesterol in patients 
with homozygous and heterozygous familial hypercholesteremia, non familial 
hypercholesteremia and mixed dyslipidemia. It also reduces the VLDL-cholesterol 
and triglyceride. Atorvastatin calcium is a synthetic lipid lowering agent, which 
competitively inhibits 3-hydroxy-3methyl-glutryl CoA.9 
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 2. REVIEW OF LITERATURE 
Oral bioavailability of drugs depends on its solubility and/or dissolution rate, 
therefore major problems associated with these drugs was its very low solubility in 
biological fluids, which results into poor bioavailability after oral administration. A 
drug with poor aqueous solubility will typically exhibit dissolution rate limited 
absorption, and a drug with poor membrane permeability will typically exhibit 
permeation rate limited absorption.10 
Drug absorption from the gastrointestinal (GI) tract can be limited by a 
variety of factors with the most significant contributors being poor aqueous 
solubility and/or poor membrane permeability of the drug molecule. When 
delivering an active agent orally, it must first dissolve in gastric and/or intestinal 
fluids before it can then permeate the membranes of the GI tract to reach systemic 
circulation.11 
Based upon their permeability characteristics, the biopharmaceutics classification 
system (BCS) classifies such drugs in two major classes, i.e., Class II and IV. The BCS 
class II drugs are poorly water-soluble entities with high permeability. Most 
formulation strategies for such drugs are targeted at enhancing their fine dispersion 
at absorption level.12 
 Noyesh -Whitney equation provides some hints as to how the dissolution 
rate of even very poorly soluble compound smight be improved to minimize the 
limitations to oral availability.   
                                     dC/dt *h = AD. (Cs - C)       
 
Where, dC/dt - is the rate of dissolution, A -is the surface area available for 
dissolution, D - is the diffusion coefficient of the compound, Cs- is the solubility of 
the compound in the dissolution medium, C -is the concentration of drug in the 
medium at time t and h - is the thickness of the diffusion boundary layer adjacent to 
the surface of the dissolving compound.13 
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  To increase the dissolution rate from equation the following approaches are 
available. 
 
 To increases the surface area available for dissolution decreasing the 
particle size of drug. 
 
 Optimizing the wetting characteristics of compound surface. 
 
 To decrease the boundary layer thickness. Ensure sink condition for 
dissolution. 
 
 Improve apparent solubility of drug under physiologically relevant 
conditions. 
 
 Drug administered in fed state is a way to improve the dissolution rate. 
 
TECHNIQUES OF SOLUBILITY ENHANCEMENT 14 
There are various techniques available to improve the solubility of poorly soluble 
drugs. Some of the approaches to improve the solubility are 
Micronization: 
 Particle size reduction leads to increase in the effective surface area 
resulting in enhancement of solubility and dissolution velocity of the drug. 
Nanonization:  
    Recently, various nanonization strategies have emerged to increase the 
dissolution rates and bioavailability of numerous drugs that are poorly soluble in 
water. Nanonization broadly refers to the study and use of materials and structures 
at the nano scale level of approximately 100 nm or less. Nanonization can result in 
improved drug solubility and pharmacokinetics, and it might also decrease systemic 
side-effects 
Nanocrystals:  
 The term drug nanocrystals imply a crystalline state of the discrete particles, 
but depending on the production method they can also be partially or completely 
amorphous. 
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 Nanosuspension: 
Nanosuspensions are sub-micron colloidal dispersion of pure particles of 
drug, which are stabilised by surfactants. Nanosuspension technology solved the 
problem of drugs which are poorly aqueous soluble and less bioavailability. 
Nanoemulsion: 
Nanoemulsions are a nonequilibrium, heterogeneous system consisting of 
two immiscible liquids in which one liquid is dispersed as droplets in another liquid. 
Sonocrystallization: 
 Sonocrystallization is a novel particle engineering technique to enhance 
solubility and dissolution of hydrophobic drugs and to study its effect on crystal 
properties of drug. 
Supercritical fluid method: 
A supercritical fluid (SCF) can be defined as a dense noncondensablefluid is 
another novel nanosizing and solubilisation technology whose application has 
increased in recent years. 
Spray freezing into liquid and lyophilization:  
This technique involves atomizing an aqueous,organic, aqueous-organic 
cosolvent solution, aqueous organic emulsion or suspension containing a drugand 
pharmaceutical excipients directly into a compressed gas (i.e. carbon dioxide, 
helium, propane,ethane), or the cryogenic liquids (i.e. nitrogen, argon or 
hydrofluroethers). 
Evaporative precipitation into aqueous solution:  
This process utilizes rapid phase separation to nucleate and grow 
nanoparticles and microparticles of lipophilic drugs. 
Use of surfactant: 
                Surface active agents (surfactants) are substances which at low 
concentrations, adsorb onto the surfaces or interfaces of a system and alter the 
surface or interfacial free energy andthe surface or interfacial tension. 
Use of co-solvent: 
Cosolvent addition is a highly effective technique for enhancement of 
solubility of poorly soluble drugs. It is well-known that the addition of an organic 
cosolvent to water candramatically changes the solubility of drugs. 
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 Hydrotropy method:  
Hydrotropy is a solubilization phenomenon whereby addition of large 
amount of a second solute results in an increase in the aqueous solubility of another 
solute. The term “Hydrotropy” has been used to designate the increase in aqueous 
solubility of various poorly watersoluble compounds due to the presence of a large 
amount of additives. 
Use of salt forms:  
A major improvement in solubility and dissolution rate can be achieved by 
forming a salt. Salts of acidic and basic drugs have, in general, higher solubilities 
than their corresponding acid or base forms. 
Solvent deposition: 
In this technique drug is dissolved in a solvent like methylene chloride to 
produce a clear solution. The carrier is then dispersed in the solution by stirring and 
the solvent is removed by evaporation under temperature and pressure. 
Solubilizing agents:  
Solubilizing materials like super disintegrants such as 
crospovidone,crosscarmellose sodium and sodium starch glycolate used as 
solubilizing agents in many formulations which increase the solubilty and 
dissolution rate of poorly water soluble drugs. The superdisintegrants acts as 
hydrophilic carrier for poorly water soluble drug. 
Modification of the crystal habit:  
Polymorphism is the ability of an element or compound tocrystallize in more 
than one crystalline form. Different polymorphs of drugs are chemically 
identical,but they exhibit different physicochemical properties including solubility, 
melting point, density, texture, stability etc. 
Co-crystallisation: 
The new approach available for the enhancement of drug solubility is 
through the application of the co-crystals, also referred as molecular complexes. 
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 Complexation: 
The most common complexing ligands are cyclodextrins, caffeine, urea, 
polyethylenen glycol, N methylglucamide. Considerable increase in solubility and 
dissolution of the drug has beenachieved by the use of cyclodextrins. 
CLASSIFICATION OF SOLID DISPERSION:  
First generation solid dispersions 
First generation solid dispersions were prepared using crystalline carriers 
such as urea and sugar, which were the first carriers to be employed in solid 
dispersion. They have the disadvantage of forming crystalline solid dispersion, 
which were thermodynamically more stable and did not release the drug as quickly 
as amorphous ones.15 
Second generation solid dispersions 
          Second generation solid dispersions include amorphous carriers instead of 
crystalline carriers which are usually polymers. These polymers include synthetic 
polymers such as povidone (PVP),polyethyleneglycols (PEG) and 
polymethacrylatesas well as natural product based polymers such as 
hydroxylpropylmethyl-cellulose (HPMC), ethylcellulose, and 
hydroxypropoylcellulose or starch derivates like cyclodextrins.15 
Third generation solid dispersions 
          Recently, it has been shown that the dissolution profile can be improved if the 
carrier has surface activity or self emulsifying properties. Therefore, third 
generation solid dispersions appeared. The use of surfactant such as inulin, inutec 
SP1,compritol 888 ATO, gelucire 44/14 and poloxamer407 as carriers was shown to 
be effective in originating high polymorphic purity and enhanced in vivo 
bioavailability.15 
 
Significant properties of solid dispersion: 
There are certain parameters that are given below when successfully 
controlled, can produce improvements in bioavailability16 
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1. Particle size reduction: 
             Solid dispersion represents the last state of the size reduction. It includes the 
principle of drug release by creating a mixture of poorly water soluble drug and 
highly soluble carriers, and after dissolution of carrier, the drug get molecularly 
dispersed in dissolution medium. 
2. Wettability:  
Carriers having surface activity like cholic acid and bile salts, when used, can 
significantly increase the wettability properties of drug. Recently, in third 
generation solid dispersion surfactants have been included that is the emerging 
technique. 
3. Higher porosity: 
Solid dispersions containing linear polymers produce larger and more 
porous particles than those containing reticular polymers and therefore, result in a 
higher dissolution rate. 
4. Amorphous state of drug particles:  
Drug particles in amorphous state have higher solubility. 
5. Approaches for avoiding drug recrystallisation 
Recrystallisation is the major disadvantage of solid dispersions, as we are 
using amorphous drug particles and they are thermodynamically instable and have 
the tendency to change to a more stable state. Several polymers are being used for 
improving the physical stability of the amorphous drugs by increasing the Tg of the 
miscible mixture. 
 
CHARACTERISATION OF SOLID DISPERSION: 
Solid dispersions are characterized fir crystallanity and molecular structure 
in amorphous solid dispersion. Various different types of analytical methods are 
available to characterize solid dispersion.17 
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 DETECTION OF CRYSTALLINITY IN SOLID DISPERSIONS: 
Many attempts have been to investigate the molecular arrangement in solid 
dispersions.  However, most effort has been put into differentiate between 
amorphous and crystalline material. For that purpose many techniques are available 
which detect the amount of crystalline material in the dispersion. The amount of 
crystalline material is never measured directly but is mostly derived from the 
amount of crystalline material in the sample. It should be noted that through the 
assessment of crystallinity as method to determine the amount of amorphous drug 
it will not be revealed whether the drug is present as amorphous drug particles or 
as molecularly dispersed molecule. 
1. Powder x-ray diffraction (xrd) 
2.  Infrared   Spectroscopy (ir) 
3.  Water Vapoursorption 
4.  Isothermal Microcalorimetry  
5.  Dissolution Calorimetry 
6.  Diffrential scanning Calorimetry (dsc) 
 
Factors affecting solubility: 18 
Particle size 
        The size of the solid particle influences the solubility because as a particle 
becomes smaller, the surface area to volume ratio increases. 
Temperature 
         Temperature will affect solubility. If the solution process absorbs energy then 
the solubility will be increased as the temperature is increased. 
Pressure 
          For gaseous solutes, an increased in pressure increases solubility and a 
decreases in pressure decreases the solubility. 
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 Nature of the solute and solvent 
         While only 1 gram of lead chloride can be dissolved in 100gm of water at room 
temperature, 200gm of zinc chloride can be dissolved. 
Molecular size  
        Molecular size will affect the solubility. The large the molecule or the higher its 
molecular weight the less soluble the substance. 
Polarity 
     Polarity of the solute and solvent molecules will affect the solubility. 
Polymorphism 
    A solid has a rigid form and a definite shape. The shape or habit of a crystal of a 
given substance may vary but the angles between the faces are always constant.18 
Advantages of solid dispersion: 
1. Rapid dissolution rates that result in an increase in the rate and extent of the 
absorption of the drug, and are duction in pre systemic both can lead to the need for 
lower doses of the drug. 
2. Other advantages include transformation of the liquid form of the drug into a 
solid form (e.g., clofibrate and benzoyl benzoate can be incorporated into PEG 6000 
to give a solid, avoidance of polymorphic changes and 
There by bio-availability problems), as in the case of nabilone and PVP dispersion, 
and protection of certain drugs by PEGs (e.g., cardiac glycosides) against 
decomposition by saliva to allow buccal absorption.16. 
 
 DISADVANTAGES OF SOLID DISPERSIONS 
The major disadvantages of SDs are related to their instability. Several 
systems have shown changes in crystallinity and a decrease in dissolution rate on 
ageing. By absorbing moisture, phase separation, crystal growth or a change from 
metastable crystalline form to stable form can take place which leads to the 
reduction of drug solubility .Moisture and temperature have more of deteriorating 
effect on solid dispersions than on physical mixtures. Sometimes it is difficult to 
handle because of tackiness.19 
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 Limitations of solid dispersion: 
The major limitation in the development of solid dispersion is the lack of 
suitable Manufacturing techniques that could be scaled up to commercial 
production. The various                                limitations are: 16 
 Laborious and expensive methods of preparation, 
 Reproducibility of physicochemical characteristics, 
 Difficulty in incorporating into formulation of dosage forms, 
 scale-up of manufacturing process, and Stability of the drug and vehicle 
 
APPLICATIONS OF SOLID DISPERSION 
 To obtain a homogeneous distribution of a small amount of drug in solid 
state. 
 To stabilize the unstable drug. 
 To dispense liquid (up to 10%) or gaseous compounds in a solid dosage. 
 To formulate a fast release primary dose in a sustained released dosage form. 
 To increase the solubility of poorly soluble drugs thereby increase the 
dissolution rate, absorption and bioavailability.  
 To stabilize unstable drugs against hydrolysis, oxidation, recrimination, 
isomerisation, photo oxidation and other decomposition procedures.  
 To reduce side effect of certain drugs.  
 Masking of unpleasant taste and smell of drugs.  
 Improvement of drug release from ointment creams and gels.  
 To avoid undesirable incompatibilities.20,21 
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 Tabel.1 Classification of Carriers Enhancing Dissolution of Drugs18 
 
 
S.NO 
 
Chemical Class 
 
Examples 
1  Acids  Citric acid, Tartaric acid, Succinic acid  
2  Sugars  Dextrose, Sorbitol, Sucrose, Maltose, 
Galactose, Xylitol  
3  Polymeric Materials  Polyvinylpyrrolidone, PEG-4000, PEG-
6000,  
Carboxymethyl cellulose, Hydroxypropyl 
cellulose,  
Guar gum, Xanthan gum, Sodium 
alginate, Methyl  
cellulose, HPMC, Dextrin, Cyclodextrins,  
Galactomannan  
4  Surfactants  Polyoxyethylene stearate, Poloxamer,  
Deoxycholic acid, Tweens and Spans,  
Gelucire 44/14, Vitamine E TPGS NF  
5  Miscellaneous  Pentaerythritol, Urea, Urethane,  
Hydroxyalkyl xanthines  
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 Fig.1 Methods of Preparation of Solid Dispersion 
 
 
 
Fusion Method 
The melting or fusion method, first proposed by Sekiguchi and Obi involves 
the preparation of physical mixture of a drug and a water-soluble carrier and 
heating it directly until it melted. The melted mixture is then solidified rapidly in an 
ice bath under vigorous stirring. The final solid mass is crushed, pulverized and 
sieved. However many substances, either drugs or carriers, may decompose or 
evaporates during the fusion process which employs high temperature. Some of the 
means to overcome these problems could be heating the physical mixture in a 
sealed container or melting it under vacuum or in presence of inert gas like nitrogen 
to prevent oxidative degradation of drug or carrier.20 
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 Advantages 
 The main advantage of direct melting method is its simplicity and economy. 
 In addition melting under vacuum or blanket of an inert gas such as nitrogen 
may be employed to prevent oxidation of drug or carrier.20 
Disadvantages 
 Firstly, a major disadvantage is that the method can only be applied when 
drug and matrix are compatible and when they mix well at the heating 
temperature 
 A problem can arise during cooling when the drug-matrix miscibility 
changes. In this case phase separation can occur. It was observed that when 
the mixture was slowly cooled, crystalline drug occurred, whereas fast 
cooling yielded amorphous solid dispersions. 
 Degradation of the drug and or matrix can occur during heating to 
temperatures necessary to fuse matrix and drug. For example, to melt a 
sugar matrix of galactose a temperature of 169°C was required and in order 
to get the glassy PVP in the rubbery state a temperature of about 170°C is 
required. Poly ethylene glycols melt at around 70°C and are therefore often 
used for the preparation of solid dispersions with the fusion method.22 
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 Work done so far to improve the solubility of atorvastatin calcium 
1. Preparation, characterization and In-vitro evaluation of atorvastatin calcium 
solid    dispersions with various hydrophilic polymers and its FDT 
formulation. (Bhumikasharma et al., 2012)23. 
2. Enhancement of dissolution for improving bioavailability of poorly water 
soluble drug through oral mucosa (Tapan K. pal et al., 2012)24. 
3. Formulation and evaluation of solid dispersion of Atorvastatin with various 
carriers (K.R.Bobe et al., 2011)25. 
4. Enhancement of dissolution rate of atorvastatin calcium using solid 
dispersions by dropping method. (Lakshmi narasaiah et al., 2011)26.  
5. Water solubility enhancement of atorvastatin by solid dispersion method 
(Riazuddin et al., 2010)27. 
6. Formulation and characterization of atorvastatin calcium liquid solid 
compacts. (Sanjeev raghavendra gubbi et al., 2010)28. 
       7. Improved dissolution rate of atorvastatin calcium using solid dispersions with       
PEG-4000(Kalyan reddy .B et al., 2010)29. 
8.   Enhancement of dissolution for improving bioavailability of poorly water 
soluble    drug through oral mucosa (Tapan K. pal et al., 2012)30. 
9.  A novel drug-drug solid dispersion of hydrochlorothiazide-losartan 
potassium  (N.N Rajendran., et al 2010)31. 
       10.  In vitro availability of atorvastatin in presence of losartan (safed arayne M.et    
al.,2006)32. 
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                                     3.  AIM AND OBJECTIVE 
 
AIM: 
To Prepare and evaluate the novel drug – drug solid dispersion of 
Atorvastatin calcium – Losartan potassium and to improve the solubility of 
atorvastatin calcium by fusion method.  
 
OBJECTIVE 
To estimate the following parameters.  
 FTIR analysis of pure drugs, physical mixtures and solid dispersions. 
 Calibration curve of atorvastatin calcium. 
 Calibration curve of losartan potassium. 
 Preparation of physical mixtures (1:2, 1:4, 1:8 ratios). 
 Preparation of solid dispersions (1:2, 1:4, 1:8 ratios). 
 Phase solubility study of Atorvastatin calcium - Losartan potassium. 
 In-vitro dissolution of pure drugs, physical mixtures and solid dispersions. 
 Release kinetic study. 
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4. PLAN OF WORK 
PREFORMULATION STUDY 
         ESTIMATION OF DRUGS 
    PREPARATIONS    EVALUATIONS 
METHOD I 
Calibration curve of 
Atorvastatin 
METHOD II 
Mixed standard 
calibration curve 
      PHYSICAL MIXTURE 
(Atorvastatin calcium) and 
Losartan potassium [1:2, 1:4, 1:8]) 
      SOLID DISPERSION 
(Atorvastatin calcium and Losartan 
potassium [1:2, 1:4, 1:8]) 
FTIR analysis 
Phase solubility 
study 
In-vitro dissolution 
study 
  
 
 
  
 
 
 
 
PROFILES 
 
 
 
 
 
 
 
 
 
 
 
  
5. PROFILES 
DRUG PROFILE 
Atorvastatin calcium32 
Category                                  : Antihyperlipidermic agent 
Empirical formula                  : C66 H68 CaF2N4010.3H2o 
Molecular weight                         : 1209.42 
Chemical structure                          : 
                                                                   
Solubility                                         : Very slightly soluble in water, slightly soluble in   
                                                     Ethanol, freely soluble in methanol 
Chemical name     : Calcium -2-(p-fluorophenyl )-beta, delta-dihydroxy-5-                  
                                                 Isopropyl-3-phenyl-4-(phenylcarbamoly) pyrrole-1-
heptan    
                                                 oic  acid (1:2)trihydrate. 
Functional category              : HMG-CoA reductase inhibitors. 
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 Pharmacology 
Mechanism of Action  
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the 
ratelimiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to 
mevalonate, a precursor of sterols, including cholesterol. Cholesterol and 
triglycerides circulate in the bloodstream as part of lipoprotein complexes. With 
ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), 
IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL 
(very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the 
liver are incorporated into VLDL and released into the plasma for delivery to 
peripheral tissues. LDL is formed from VLDL and is catabolized primarily through 
the high-affinity LDL receptor. Clinical and pathologic studies show that elevated 
plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and 
apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for 
developing cardiovascular disease, while increased levels of HDL-C are associated 
with a decreased cardiovascular risk. 
Pharmacokinetics 
Absorption:  
Atorvastatin is rapidly absorbed after oral administration; maximum 
plasmaconcentrations occur within 1 to 2 hours. Extent of absorption increases in 
proportion toatorvastatin dose. The absolute bioavailability of atorvastatin (parent 
drug) isapproximately 14% and the systemic availability of HMG-CoA reductase 
inhibitoryactivity is approximately 30%. The low systemic availability is attributed 
to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass 
metabolism. Although food decreases the rate and extent of drug absorption by 
approximately 25% and 9%,respectively, as assessed by Cmax and AUC, LDL-C 
reduction is similar whether atorvastatin is given with or without food. Plasma 
atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) 
following evening drug administration compared with morning. However, LDL-C 
reduction is the same regardless of the time of day of drug administration. 
19 
 Distribution: 
Mean volume of distribution of atorvastatin is approximately 381 liters. 
Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of 
approximately 0.25 indicates poor drug penetration into red blood cells. Based on 
observations in rats, atorvastatin is likely to be secreted in human milk. 
Metabolism  
Atorvastatin is extensively metabolized to ortho- and parahydroxylated 
derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA 
reductase by ortho- and parahydroxylated metabolites is equivalent to that of 
atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA 
reductase is attributed to active metabolites. In vitro studies suggest the importance 
of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased 
plasma concentrations of atorvastatin in humans following coadministration with 
erythromycin, a known inhibitor of this isozyme. 
Excretion 
Atorvastatin and its metabolites are eliminated primarily in bile following 
hepatic and/or extra-hepatic metabolism; however, the drug does not appear to 
undergo 3enterohepatic recirculation. Mean plasma elimination half-life of 
atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory 
activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active 
metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following 
oral administration. 
Duration 
           The haff curve of HMG-CoA reductase inhibition is 20 to 30 hours. 
Contraindications 
Active liver disease or unexplained persistent elevation of serum 
transaminases; pregnancy;lact. 
20 
Dosage and Administration 
 Adults 
10 to 80 mg/day. 
Pharmacodynamics 
Adverse Reactions 
CNS                                : Headache, Asthena, dizziness, insomnia. 
ENT                                : Sinusitis, Pharyangitis, Rhinitis. 
Dermatologic           : Rash, Stevens-johnson syndrome, bullous rashes including  
                                          erythema multiforme Toxic epidermal necrolysis 
GI                                   : Sinusists,abdominal pain, constipation, dyspepsia, Nausea. 
Genitourinary         : Albuminuria, Hematuria. 
Metabolic                  : Peripheral edema (at least 2%) 
Musculoskeletal     : Myalgia, Arthralgia, Arthritis, Rhabdomyolysis. 
Respiratory              : Bronchitis 
Miscellaneous         : Accidental injury, flu-like symptoms, chest pain, Angioneurotic             
                                         edema. 
Drug Interaction 
                       Co administration of Antacids, Cholestrol, rifampin may decrease 
atorvastatin level.Azole antifungal agent (eg,itraconazole), cyclosporine, diltiazem, 
gemfibrozil, grapefruit juice, macrolide antibiotics (eg,erythromycin), 
niacin,NNRTIs, protease inhibitors (eg,ritonavir), verapamil, severe myopathy or 
rahabdomyolysis may occur. 
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 LOSARTAN POTASSIUM33 
Category                                  : Antihypertensive   
Empirical formula                  : C22H22ClKN6O 
Molecular weight                        : 461.01 
Solubility                                   : freely soluble in water, soluble in alcohols, and slightly                                             
                                                      Soluble in organic solvents, such as acetonitrile and       
                                                      methyl ethyl ketone.             
Chemical structure                          : 
                                                                
Chemical name                   : 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-
4-   
                                            yl]methyl]-1H-imidazole-5-methanol monopotassium salt. 
Mechanism of Action  
 Angiotensin II [formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the 
primary vasoactive hormone of the renin-angiotensin system and an important 
component in the pathophysiology of hypertension. It also stimulates aldosterone 
secretion by the adrenal cortex. Losartan and its principal active metabolite block 
the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively 
blocking the binding of angiotensin II to the AT1receptor found in many tissues, 
(e.g., vascular smooth muscle, adrenal gland). There is also an AT2receptor found in 
many tissues but it is not known to be associated with cardiovascular homeostasis. 
Both losartan and its principal active 
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 metabolite do not exhibit any partial agonist activity at the AT1 receptor and have 
much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 
receptor.  In vitro binding studies indicate that losartan is a reversible, competitive 
inhibitor of the AT1 receptor. The active metabolite is 10 to 40 times more potent by 
weight than losartan and appears to be a reversible, non-competitive inhibitor of the 
AT1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the 
enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor 
do they bind to or block other hormone receptors or ion channels known to be 
important in cardiovascular regulation. 
Pharmacokinetics 
Following oral administration, losartan is well absorbed and undergoes 
substantial first-passs metabolism. The systemic bioavailability of losartan is 
approximately  33%,  About  14%  of  an  orally administered  dose  of  losartan  is  
converted  to  the active metabolite. Mean peak plasma concentrations of losartan 
and its active metabolite are reached in 1 hour and 3-4hours  respectively. While  
maximum plasma  concentrations  of  Losartan  and  its  active metabolite are 
approximately equal, the AUC of the metabolite  is  about  4  times  as  great  as  that  
of Losartan. A meal slows  absorption of losartan  and decreases  its  Cmax-but  has  
only  minor  effects  on losartan AUC or on the AUC of the metabolite (about 10%  
decrease).  Both  Losartan  and  its  active metabolite  are  highly  bound  to  plasma  
proteins, primarily albumin, with plasma free fractions of 1.3% and 0.2% 
respectively. Studies in rats indicate that Losartan crosses the blood-brain barrier 
poorly, if at all about 4% of the dose is excreted unchanged in urine and about 6% is 
excreted unchanged in urine as active metabolite. Biliary excretion contributes to the 
elimination of Losartan and its metabolites. Losartan pharmacokinetics have not 
beeninvestigated  in  patients  <18  years  of  agem Losartan pharmacokinetics  have  
been  investigated  in  the elderly(65-75  years)  and  in  both  genders.  Plasma 
concentrations of losartan and its active metabolite are similar in elderly and young 
hypertensives. Plasma concentrations of losartan are about twice as high in female 
hypertensives as in male hypertensives. But concentrations of the active metabolite 
are similar in males and females. No dosage adjustment is necessary. 
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 INDICATIONS 
 Losartan potassium is indicated for the treatment of mild to moderate 
hypertension. It may be used alone or in combination with other antihypertensive 
agents. 
Dosage and Administration 
Hypertension 
Adult’s Initial dose  
PO 50 mg/day; 25 mg/day if volume depleted or history of hepatic impairment. 
Maintenance dose  
PO 25 to 100 mg/day. 
Children 6 yr of age and older Initial dose  
PO 0.7 mg/kg (max, 50 mg) once daily. 
Maintenance dose  
PO 0.7 to 1.4 mg/kg/day (max, 100 mg). 
Nephropathy in Type 2 Diabetes Adults Initial dose  
PO 50 mg/day; the dose may be increased to 100 mg/day based on BP response 
Drug Interactions: 
Losartan may increase levels of blood potassium (hyperkalemia), which can lead to 
serious heart problems (arrhythmias). Therefore, concomitant use of other drugs or 
substances that increase blood-such as potassium-sparing diuretics (for 
example, spironolactone [Aldactone], triamterene, and amiloride), potassium 
supplements, or salt substitutes containing potassium may lead to dangerous 
increases in serum potassium.Combining losartan or other ARBs with non steroidal 
anti-inflammatory drugs (NSAIDs) in patients who are elderly, fluid-depleted 
(including those on diuretic  
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 therapy), or with poor kidney function may result in reduced kidney function, 
including kidney failure. These effects usually are reversible. The antihypertensive 
effect of losartan may be reduced by aspirin and other NSAIDs such 
as ibuprofen (Advil, Children's Advil/Motrin, Medipren, Motrin, Nuprin, PediaCare 
Fever, etc.), indomethacin (Indocin, Indocin-SR), and naproxen (Anaprox, Naprelan, 
Naprosyn, Aleve).  
 Losartan potassium was negative in the microbial mutagenesis and V-79 
mammalian cell mutagenesis assays and in the in vitro alkaline elution and in vitro 
and in vivo chromosomal aberration assays. In addition, the active metabolite 
showed no evidence of genotoxicity in the microbial mutagenesis, in vitro alkaline 
elution, and in vitro chromosomal aberration assays.  
 Fertility and reproductive performance were not affected in studies with 
male rats given oral doses of losartan potassium up to approximately 150 
mg/kg/day. The administration of toxic dosage levels in females (300/200 
mg/kg/day) was associated with a significant (p<0.05) decrease in the number of 
corpora lutea/female, implants/female, and live fetuses/female at C-section. At 100 
mg/kg/day only a decrease in the number of corpora lutea/female was observed. 
The relationship of these findings to drug treatment is uncertain since there was no 
effect at these dosage levels on implants/pregnant female, percent post-
implantation loss, or live animals/litter at parturition. In non pregnant rats dosed at 
135 mg/kg/day for 7 days, systemic exposure (AUCs) for losartan and its active 
metabolite were approximately 66 and 26 times the exposure achieved in man at 
the maximum recommended human daily dosage (100 mg) 
Contraindications 
Losartan potassium is contraindicated in patients who are hypersensitive to any 
component of this product 
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 6. MATERIALS AND METHODS 
 
ACTIVE INGREDIENTS USED: 
                                   Table 2: Ingredients used for the experiment 
S. 
No 
          Name of the ingredient                         Manufacturer/Suppliers 
   1.          Atorvastatin calcium Dr.Reddy’S Laboratories,Ltd. 
  2.           Losartan potassium   USP Medrich Pvt. Ltd. 
 
INSTRUMENTS USED:  
                                   Table 3: Instruments used for the experiment 
S. No             Name of the instrument                     Manufacturing company 
 
1. 
 
UV – Spectrophotometer 
 
Perkin Elmer 
 
2. 
 
FTIR-Spectrophotometer 
 
Perkin Elmer spectrum RX1 FT-IR 
 
3. 
 
Weighing Balance 
 
Schimadzu 
 
4. 
 
 USP Programmable Dissolution 
Apparatus 
 
Veego 
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7. METHODOLOGY 
ESTIMATION OF PURE DRUGS, PHYSICAL MIXTURES AND   SOLID   DISPERSIONS 
Preparation of Standard Solutions 
 Standard solution of 100mg each of Losartan potassium and atorvastatin 
calcium were carried out using phosphate buffer (pH 6.8). 
Mixed Standard 
 This method was adapted to pure Atorvastatin and losartan 
potassium.100mg was accurately weighed and dissolved in phosphate buffer (pH 
6.8). Further, dilutions were made to get 1, 2, 3, 4 & 5µg/ml the sample points 236nm 
for Losartan potassium and 248nm for atorvastatin calcium. A standard curve was 
constructed by plotting the absorbance vs. concentration of the drug taken. 
 Preparation of PH 6.8 phosphate buffer  
          Placed 50 ml of 0.2 M Potassium dihydrogen phosphate in a 200 ml volumetric 
flask, added specified volume of 22.4 ml of 0.2 M NaOH and then added water to 
make the volume. 
0.2 M Potassium dihydrogen phosphate 
          Dissolve 27.218 gm of potassium dihydrogen phosphate in distilled water and 
dilute to 1000 ml with distilled water. 
0.2 M NaOH solution 
          Dissolved 8 gm of NaOH in distilled water and diluted to 1000 ml with distilled 
water. 
 
27 
  
PREPARATION OF PHYSICAL MIXTURE AND SOLID DISPERSION: 
Preparation of physical mixture 
             Atorvastatin calcium and Losartan potassium were   accurately weighed at the 
ratio of 1:2, 1:4; 1:8 (10: 20mg, 10: 40mg, 10: 80mg) pulverized, and then mixed 
thoroughly in a glass mortar with pestle until it becomes homogenous. The mixtures 
were passed through a 250µm sieve for further evaluation. 
Preparation of solid dispersion 
Solid dispersion of Atorvastatin calcium and Losartan potassium at three 
ratios of 1:2, 1:4, 1:8 (10:20mg, 10:20mg, 10:80mg) was prepared by fusion method. 
Atorvastatin calcium and Losartan potassium was heated it directly until it is melted. 
The melted mixture was then solidified rapidly in an ice-bath under vigorous stirring. 
The final solid mass was crushed and pulverized. After dried solid dispersion was 
passed through a 250µm sieve. Sample was stored in a desiccators and used for 
further investigation. 
 
                 Table.4  Formulation of physical mixtures and solid dispersions of 
                             Atorvastatin calcium - Losartan potassium 
S.NO          Physical mixture (AVT:LSP)             Solid dispersion (AVT:LSP) 
1.       1:2 F1PM       1:2 F1SD 
2.       1:4 F2PM       1:4 F2SD 
3.       1:8 F3PM       1:8 F3SD 
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 Evaluation of formulations   
The prepared formulations of solid dispersion and physical mixture were evaluated 
for the following          
a. Physico-chemical characterization. 
b. In vitro dissolution studies 
PHYSICO CHEMICAL CHARACTERIZATION: 
Compatibility study 
Fourier transform infrared spectroscopy was employed to characterize the 
possible interactions between the Atorvastatin calcium and Losartan potassium. In 
this study pure drug, physical mixture, solid dispersions were studied by FTIR 
spectrophotometer. 
Estimation of Drug Content AVT 
 For drug content uniformity test,  The powder equivalent to 10 mg of AVT was 
dissolved in about 10 ml of methanol an transferred into 100 ml of  volumetric flask 
and volume was made up using phosphate buffer (pH 6.8) and the solution was 
filtered using (Whatmann No. 1 filter paper). The AVT content in the filtrate was 
determined by measuring the absorbance at 248 nm using UV spectrophotometer 
after appropriate dilution with phosphate buffer (pH 6.8). The drug content was 
determined using the standard calibration curve. 
Estimation of Drug Content LSP 
 For drug content uniformity test,  The powder equivalent to 10 mg of LSP was 
dissolved in about 10 ml of methanol an transferred into 100 ml of  volumetric flask 
and volume was made up using phosphate buffer (pH 6.8) and the solution was 
filtered using (Whatmann No. 1 filter paper). The AVT content in the filtrate was 
determined by measuring the absorbance at 248 nm using UV spectrophotometer 
after appropriate dilution with  
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 phosphate buffer (pH 6.8). The drug content was determined using the standard 
calibration curve. 
Determination of phase solubility of Atorvastatin calcium/ Losartan 
potassium  
 Drug solubility studies were performed in triplicate by adding excess amount of ATV 
to distilled water and buffer solutions having different pH (6.8). Solutions containing 
flasks were kept on a Rotary Shaking Incubator for 24 hrs. After 24 hrs, solutions 
were analysed using UV spectrophotometer. 
In vitro Dissolution study 
In vitro dissolution studies of the pure drug (AVT), the selected ratios of solid 
dispersions and physical mixtures (equivalent to 10mg ATV filled in hard gelatin 
capsules using stainless steel sinkers) were performed using USP type II (Paddle) 
apparatus with paddle rotating at 75 rpm in 900ml of phosphate buffer pH 6.8 at 37 
± 0.5ºC. At fixed time intervals, 5ml samples were withdrawn, filtered and replaced 
with phosphate buffer pH 6.8. Concentration of AVT in each sample was determined 
by UV spectrophotometer.  
 
KINETIC ANALYSIS OF IN VITRO RELEASE RATES OF    FORMULATIONS  
          The results of in vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows:- 
1. Zero-order kinetic model-cumulative percentage drug release versus time. 
2. First- order kinetic model-log cumulative percentage drug release remaining 
versus time. 
1. Zero-order kinetics 
          Zero order release would be predicted by the following equation:- 
At = A0 - K0 t 
30 
 Where, 
                 At = Drug release at time 't' 
                 A0 = Initial drug concentration 
                 K0 = Zero order rate constant (hr-1) 
          When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to 
K0. 
 
 
2. First- order kinetics 
          First-order release would be predicted by the following equation:- 
Log C = log C0 - Kt /2.303 
                                    
                   Where, 
                               C=Amount of drug remained at time t 
                              C0=Initial amount of drug 
                               K=First-order rate constant (hr-1) 
              When the data is plotted as log cumulative percent drug remaining versus 
time yields a straight line, indicating that the release follow first order kinetics. The 
constant K can be obtained by multiplying 2.303 with slope values. 
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8. RESULTS 
                                            
   Table. 5 Calibration data of Atorvastatin calcium 
 
 
S.NO. 
 
   Concentration of 
atorvastatin 
calcium(µg/ml) 
 
Absorbance at 248nm 
0 0 0 
1 1 0.0625 
2 2 0.1142 
3 3 0.1856 
4 4 0.2452 
5 5 0.3107 
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Fig.2
calibration curve of Atorvastatin calcium
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Table. 6 Calibration data of Losartan potassium 
S.NO Concentration of 
Losartan 
potassium(µg/ml) 
 
 
Absorbance 
at 236nm 
0 0 0 
1 1 0.0656 
2 2 0.1290 
3 3 0.1825 
4 4 0.2482 
5 5 0.3166 
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calibration curve of losartan potassium
 Compatibility study (Fourier transform infrared spectroscopic studies) 
 Fourier transform infrared spectroscopy was employed to characterize the 
possible interactions between the Atorvastatin calcium and Losartan potassium. In 
this study pure drug, physical mixture, solid dispersions were studied by FTIR 
spectrophotometer 
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 Fig.4 FTIR SPECTRA OF PURE ATORVASTATIN CALCIUM 
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 Fig.5 FTIR SPECTRA OF PURE LOSARTAN POTASSIUM 
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 Fig.6 FTIR SPECTRA OF AVT AND LSP (F2PM) (1:4) 
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 Fig.7 FTIR SPECTRA OF HCT AND LSP (F3PM) (1:8) 
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 Fig.8 FTIR SPECTRA OF HCT AND LSP (F2SD) (1:4) 
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 Fig.9 FTIR SPECTRA OF HCT AND LSP (F3SD) (1:8) 
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 ESTIMATION OF DRUG CONTENT 
       Both methods I and II produced linearity in the graph obtained by plotting 
concentration versus absorbance. There was no interference in the analysis of drugs.   
       Table. 7 Calibration curve data for Atorvastatin calcium-Losartan Potassium       
absorbance in combination   
                                                           
 
S.No 
 
Concentration 0f drug 
(µg/mL) 
Absorbance   of  
Atorvastatin calcium 
 At 248nm 
Absorbance of 
Losartan potassium 
at 236nm 
1 10 0.02 0.03 
2 20 0.73 0.82 
3 30 1.44 1.72 
4 40 2.19 2.58 
5 50 2.78 3.25 
6 60 3.57 4.01 
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Calibration curve of Atorvastatin calcium and Losartan 
potassium 
ATV
LSP
 PHASE SOLUBILITY STUDY 
Phase solubility study was carried out in order to ascertain the effect of LSP 
on the solubility characteristics of AVT. The results are presented in Table -8 and 
Figure -11. Solubility of AVT was increased as the concentration of LSP increased. 
The solubility of AVT was minimal in PH 6.8 and increased approximately eight fold 
at 0.01% w/v of LSP in 6.8buffer. These data indicates that LSP in PH 6.8 acted as a 
new vehicle and solubility of AVT was greatly enhanced, possibly due to the solvent 
effect of LSP.    
Table. 8 
S.No 
Concentration of Losartan 
Potassium (%w/v) 
Solubility of  Atorvastatin calcium 
in Losartan potassium solution 
(mg/ml) 
1 0 0.2123 
2 0.0025 0.3610 
3 0.0050 0.5270 
4 0.010 0.010 
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Effect of Losartan Potassiumon on Solubility of 
atorvastatin Calcium
 In-vitro dissolution studies 
The data of the In vitro dissolution studies as cumulative % drug release Vs 
time performed on PMs and SDs on PH 6.8 buffer there were differences in 
dissolution pattern of AVT between F1PM, F2PM and F3PM formulations. The % 
drug dissolved at every time point intervals was statistically analyzed and it was 
observed at 10 min. The % drug dissolved from PMs was found to increase as the 
concentration of LSP is increased and all the PMs showed about 90% release of AVT 
in 80min. When compared with pure AVT PMs showed faster dissolution while pure 
AVT dissolved 59% at 90 min the PM dissolved 90% AVT in 80min.Thus showing 
faster dissolution of AVT from PMs as compared to pure AVT. Though there was a 
significant difference in dissolution pattern of AVT from PMs at different time 
intervals, no significant difference was observed in dissolution pattern all PMs at 80 
min, at which fine point 90% dissolution of AVT was observed. Since LSP is freely 
soluble in dissolution media a uniform dissolution pattern of this drug was observed 
from PMs. SDs showed similar dissolution pattern as observed with PMs at different 
time point intervals and there were significant differences in percent (AVT) drug 
dissolved between different time point intervals. However SDs showed faster 
dissolution of AVT as compared to PMs. 90% dissolution of AVT was at shorter time 
(50min) from F3SD formulation as compared to F1SD, F2SD formulations which 
showed 90% dissolution of AVT at longer time (70min). These finding suggests that 
SDs showed faster dissolution rate of AVT as compared to PM or pure drug. The 
enhanced dissolution of AVT from PMs is due to the solvent effect of LSP. The 
magnitude of dissolution was significantly higher from SDs as compared to PMs the 
mechanisms for improved dissolution of AVT from SD is due to firstly, the solvent 
effect of LSP on the solubility of AVT; Secondly the change of physical state of AVT 
from crystallinity to amorphous state  and thirdly possible micronization of poorly 
soluble AVT, reduced particle size, larger surface area and so enhanced dissolution of 
the drug in the environment. The dissolution pattern of LSP whether from PM or 
from SD assumes no significance in the study as the drug is freely soluble. 
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 Table. 9 In-Vitro Dissolution Profile of Pure Atorvastatin calcium 
Time(min) Trail 1 Trail 2 Trail 3 Mean cumulative 
%drug release 
0 0 0 0 0 
10 3.04 3.42 3.86 0.344±0.410 
20 8.90 9.20 9.28 9.12±0.200 
30 14.36 13.86 14.33 14.18±0.280 
40 19.17 19.83 18.94 19.31±0.462 
50 25.60 25.47 26.26 25.77±0.423 
60 33.82 34.44 33.59 33.95±0.439 
70 44.93 44.46 45.21 44.86±0.379 
80 53.26 52.71 52.89 52.95±0.280 
90 58.63 58.82 60.06 59.17±0.776 
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 Table. 10 In-Vitro Dissolution Profile of Pure Lossartan potassium 
Time(min) Trail 1 Trail 2 Trail 3 Mean cumulative 
%drug release 
 
0 0 0 0 0 
10 78.14 77.36 78.94 78.14±0.210 
20 79.77 80.08 80.29 82.04±0.261 
30 83.78 84.26 84.41 84.15±0.329 
40 87.15 86.92 87.33 87.13±0.205 
50 90.42 89.34 89.75 89.17±0.365 
60 91.92 92.45 92.28 92.21±0.270 
70 94.55 93.94 94.40 94.29±0.317 
80 95.05 95.68 95.20 96.31±0.329 
90 97.85 97.26 97.42 98.17±0.294 
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 Table. 11 In-vitro Dissolution Profile for F1PM 
                  Atorvastatin calcium 
 
               Losartan Potassium 
Time 
(min) 
Trail 
1 
Trail 2 Trail 
3 
Mean ± SD 
Trail 
1 
Trail 
2 
Trail 
3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 21.08 20.63 21.46 21.05±0.415 
 
79.61 80.03 80.17 79.93±0.291 
20 40.77 41.31 41.28 41.12±0.303 
 
81.92 83.06 82.12 82.36±0.608 
30 60.67 61.42 61.06 61.05±0.375 
 
84.26 83.76 84.36 84.12±0.321 
40 68.94 69.44 68.65 69.01±0.399 
 
86.20 86.34 85.82 86.12±0.269 
50 74.81 75.22 75.39 75.14±0.296 
 
88.92 90.06 89.66 89.54±0.578 
60 80.46 80.32 79.60 80.12±0.461 
 
90.30 91.77 91.81 91.293±0.860 
70 87.30 86.88 87.74 87.30±0.430 
 
91.20 92.14 92.27 91.87±0.583 
80 90.77 91.09 91.38 91.08±0.305 
 
94.39 93.71 94.40 94.16±0.395 
90 94.20 94.73 93.86 94.26±0.438 
 
95.88 96.16 95.71 95.91±0.887 
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First order plot of AVT from F1PM
 Table. 12 In-vitro Dissolution Profile for F2PM 
                 Atorvastatin calcium 
 
               Losartan Potassium 
Time 
(min) 
Trail 1 Trail 2 Trail 
3 
Mean ± SD 
Trail 
1 
Trail 2 Trail 3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 18.21 19.80 18.46 18.82±0.855 79.51 78.87 79.25 79.21±0.321 
20 36.27 36.41 35.76 36.14±0.342 82.95 84.01 83.42 83.46±0.531 
30 63.80 64.46 64.08 64.11±0.331 87.60 87.22 86.35 87.05±0.640 
40 69.63 70.24 70.16 70.01±0.331 91.17 90.75 91.41 91.11±0.334 
50 78.40 77.88 78.33 78.20±0.282 92.85 91.95 93.03 92.61±0.578 
60 83.27 83.64 82.69 83.2±0.418 93.77 94.10 94.39 94.08±0.310 
70 86.92 87.05 87.36 87.11±0.226 94.91 95.45 95.33 95.23±0.283 
80 92.66 91.82 93.08 92.52±0.641 95.79 96.25 96.53 96.19±0.373 
90 95.15 94.77 95.23 95.05±0.245 97.11 96.55 97.47 97.04±0.463 
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Zero order plot of AVT from F2 PM
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First order plot of AVT from F2PM
 Table. 13 In-vitro Dissolution Profile for F3PM 
                 Atorvastatin calcium                Losartan Potassium 
Time 
(min) 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 25.75 25.86 26.16 25.92±0.212 81.15 80.75 80.86 80.92±0.206 
20 44.76 45.08 45.35 45.06±0.296 85.72 86.07 85.87 85.88±0.175 
30 66.15 65.88 66.27 66.01±0.199 88.77 89.16 89.34 89.09±0.291 
40 71.96 73.02 72.77 72.58±0.554 92.56 93.04 92.72 92.77±0.244 
50 79.65 79.53 78.92 79.36±0.391 93.66 94.18 94.41 94.08±0.384 
60 83.72 82.95 84.06 83.57±0.568 96.29 95.56 95.35 95.73±0.493 
70 87.81 87.63 86.55 87.33±0.681 97.35 98.02 97.23 97.53±0.425 
80 92.54 92.15 91.73 92.14±0.405 98.07 97.51 97.63 97.73±0.294 
90 97.31 97.16 96.68 97.05±0.329 97.83 98.48 98.55 98.28±0.397 
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% Drug release of AVT from F3PM  
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Zero order plot of AVT froM F3PM
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First order plot of AVT From F3PM
 Table. 14 In-vitro dissolution profile for F1SD 
                    Atorvastatin calcium                Losartan Potassium 
Time 
(min) 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 24.16 24.38 23.65 24.06±0.374 78.75 79.17 79.05 78.99±0.216 
20 42.91 44.05 43.35 43.43±0.574 81.36 80.85 81.18 81.13±0.258 
30 63.17 63.41 62.75 63.11±0.334 86.66 87.14 87.25 87.01±0.313 
40 71.41 70.78 71.36 71.18±0.350 89.88 89.72 90.11 89.90±0.196 
50 80.98 82.02 81.57 81.52±0.521 93.15 92.62 92.75 92.84±0.276 
60 89.12 88.73 89.25 89.03±0.270 94.35 94.17 93.94 94.15±0.205 
70 92.26 92.44 91.72 92.14±0.374 94.91 95.15 95.22 95.09±0.162 
80 
 
94.63 95.29 95.35 95.09±0.399 96.13 96.28 95.85 96.08±0.218 
90 96.22 95.66 96.18 96.02±0.312 97.18 96.94 97.32 97.14±0.192 
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% Drug release of AVT from F1SD 
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Zero order plot of AVT From F2SD
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First order plot of AVT From F2SD
  
Table. 15 In-vitro dissolution profile for F2SD 
                Atorvastatin calcium 
 
               Losartan Potassium 
Time 
(min) 
Trail 
1 
Trail 
2 
Trail 
3 
Mean ± SD 
Trail 
1 
Trail 
2 
Trail 
3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10  18.78 19.25 19.43 19.15±0.335 80.33 79.90 80.11 80.11±0.215 
20 36.55 35.98 37.08 36.53±0.550 83.72 84.25 84.06 84.01±0.268 
30 74.33 74.09 73.85 74.07±0.240 88.28 88.16 87.92 88.12±0.183 
40 79.81 80.45 80.36 80.20±0.346 90.76 91.04 91.18 90.99±0.213 
50 86.22 86.05 85.78 86.01±0.221 93.10 93.24 93.43 93.25±0.165 
60 88.17 87.93 88.15 88.08±0.133 95.88 96.05 96.16 96.03±0.1411 
70 90.25 90.44 90.36 90.35±0.095 97.09 97.17 96.95 97.07±0.111 
80 94.41 93.75 94.17 94.11±0.334 97.14 97.05 97.32 97.17±0.135 
90 96.72 96.98 97.24 96.98±0.260 98.18 98.35 98.54 98.35±0.1801 
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Zero order plot of AVT from F2SD 
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First order plot ofAVT from F2SD
 Table. 16 In-vitro dissolution profile for F3SD 
                   Atorvastatin calcium                Losartan Potassium 
Time 
(min) 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
Trail 1 Trail 2 Trail 3 
Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 30.77 30.82 31.14 30.91±0.200 84.96 85.55 86.02 85.57±0.531 
20 56.96 57.05 57.12 57.04±0.080 89.14 88.77 89.22 89.04±0.240 
30 71.08 71.32 70.80 71.06±0.260 91.85 92.08 92.16 92.03±0.160 
40 80.78 80.93 81.23 80.98±0.229 95.11 95.20 94.90 95.07±0.153 
50 89.80 89.71 90.16 89.89±0.238 96.06 96.31 96.23 96.02±0.127 
60 92.85 93.03 93.10 92.79±0.129 96.89 97.17 97.40 97.15±0.255 
70 96.30 95.79 96.13 96.07±0.259 98.15 98.11 97.95 97.76±0.105 
80 97.55 97.22 97.40 97.39±0.165 98.12 98.10 98.33 98.18±0.127 
90 98.14 98.10 97.87 98.03±0.145 98.87 99.02 99.20 99.03±0.165 
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% Drug release of AVT from F3SD
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Zero order plot of AVT From F3SD
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First order plot of AVT from F3SD
  
Table. 17 Release kinetic study 
Formulation 
Code 
 
AVT 
 
LSP 
PHYSICAL MIXTURE SOLID DISPERSION 
F1PM F2PM F3PM F1SD F2SD F3SD 
Zero order 
“R2”value 
 
0.989 0.992 0.894 0.884 0.868 0.881 0.816 0.806 
First order 
“R2”value 
0.994 0.997 0.946 0.959 0.970 0.922 0.883 0.868 
Best fit 
model 
First 
order 
First 
order 
First 
order 
First 
order 
First 
order 
First 
order 
First 
order 
First 
order 
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Table. 18 Comparative % Dissolution of physical mixtures 
Time 
(mins) 
          F1PM           F2PM        F3PM 
  AVT LSP AVT LSP AVT LSP 
0 0 0 0 0 0 0 
10 21.05 79.93 18.82 79.21 25.92 80.92 
20 41.12 82.36 36.14 83.46 45.06 85.88 
30 61.05 84.12 64.11 87.05 66.01 89.09 
40 69.01 86.12 70.01 91.11 72.58 92.77 
50 75.14 89.54 78.20 92.61 79.36 94.08 
60 80.12 91.29 83.02 94.08 83.57 95.73 
70 87.30 91.87 87.11 95.23 87.33 97.53 
80 91.08 94.16 92.52 96.19 92.14 97.73 
90 94.26 95.91 95.05 97.04 97.05 98.28 
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Comparative drug release of physical mixture
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 Table. 19 Comparative % dissolution profile of solid dispersions 
Time 
(mins) 
     F1SD F2SD F3SD 
AVT LSP AVT LSP AVT LSP 
0 0 0 0 0 0 0 
10 24.06 78.99 19.15 80.11 30.91 85.57 
20 43.43 81.13 36.53 84.01 57.04 89.04 
30 63.11 87.01 74.09 88.12 71.06 92.03 
40 71.18 89.90 80.20 90.99 80.98 95.07 
50 81.52 92.84 86.01 93.25 89.89 96.02 
60 89.03 94.15 88.08 96.03 92.99 97.15 
70 92.14 95.09 90.35 97.07 96.07 97.76 
80 95.09 96.08 94.11 97.17 97.39 98.18 
90 96.02 97.14 96.98 98.35 98.03 99.03 
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9. DISCUSSION 
The results of the present study demonstrate that a novel drug-drug solid 
dispersion approach can improve dissolution and pharmacokinetic characteristics of 
the poorly soluble drug that was presented with the soluble drug. This novel 
approach will obviate the need for inclusion of physiological water soluble inert 
carriers in solid dispersion and so cost effective. Besides, this approach stabilizes the 
formulation from the effect of moisture that is normally encountered in solid 
dispersions prepared with physiological inert carriers.  
In the present study AVT-LSP, used in the treatment of hypertension was 
selected as a model for this novel drug – drug solid dispersion approach and its 
physiochemical, in vitro release were investigated. AVT though rapidly absorbed 
from the GIT following oral administration, its poor solubility may pose dissolution 
rate limited absorption problem. The in vitro release of solid dispersion has shown 
enhanced dissolution of AVT as compared to physical mixture or solid dispersion. 
The amorphous form of AVT was more soluble than its crystalline form and 
so an improved dissolution of AVT was observed from solid dispersion. Additionally 
LSP which is freely soluble has increased the solubility of AVT due to its solvent 
effect as shown in phase solubility study. 
The pure drug AVT at 90 min dissolved 59% of release and pure drug LSP AT 
90 min dissolved 98% of release. The PM AVT shows at 90 min dissolved 97% of 
release the PM LST shows at 90min dissolved 98% of release. The SD AVT shows at 
90min dissolved 98% of release the SD LSP shows at 90min dissolved 99% of 
release. 
The dissolution of AVT was better from AVT-LSP solid dispersion as 
compared to PM and pure drug.  
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CONCLUSION 
 
 
 
 
 
 
 
 10. CONCLUSION 
 
 The present study shows improved dissolution of AVT from a modified novel 
drug - drug solid dispersion along with LSP. 
 Dissolution of AVT was better from AVT - LSP solid dispersion as compared to 
physical mixture and pure drug. 
 This novel solid dispersion is stable as no physiological inert carriers that are  
            affected by moisture are used. 
 Cost effective and economical as this approach is free of the economical   
            burden of physiological inert carriers. 
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